India Cervical Cancer Screening Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Cervical cancer is an important area of action for any cancer control programme because of the burden of disease, and the potential for effective prevention through screening. Cervical cancer hardly presents any symptoms in its early stages and it highlights the importance of regular screening for the disease. Screening is looking for cancer before a person has any symptoms. This can help to find the cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat.
Screening programs involve the testing of asymptomatic individuals with a precise screening test to identify those who likely to have the disease of interest and for the further investigation to confirm or exclude the disease. The aim of cancer screening is to prevent the cancer deaths and to improve the quality of life by finding cancers in early stage and by effectively treating them.
A choice to familiarize a screening program in public health services depends on the evidence that the benefits overshadow the harms of screening, disease burden, availability of suitable screening test, effective treatment, adequate resources, and efficient health services. Screening programs should achieve high participation for testing, diagnosis, and treatment. The population based cervical cancer screening programs have not yet been executed in many of the developing countries, despite the fact that cervical cancer has the greatest burden in developing countries, which is largely related to poverty, lack of resources and infrastructure and disqualification of women.
India accounts for 25% of global cervical incidences and death in annually in India. At present Women population accounts for approximately 49% of total Indian population. Among the total female population base, urban woman appears to be much aware of cervical screening test as compared to rural counterparts. Currently, there are VIA and Pap Smear test most common for cervical screening, but have their own disadvantages like inconvenience and less predictive and more confirmatory and surgical in nature.
Cervical cancer screening market in India is in still infancy stage. Currently the market is highly unorganized in the nature as most of the screening tests are performed in hospitals or under public programmes. The demand for cervical cancer screening is expected to rise with increasing awareness and growing concerns regarding second most common type of cancer causing large number of deaths among women in the country. The current degree of competition in terms of cervical screening in Indian is minimal with the availability of 2-3 players in the market.
There exist ample unexplored opportunity for various stake holders of the cervical screening market in India. Currently there is no big player in the market having national or regional level reach in Indian market. The entry restraints are minimal except the initial level of investment required to setup the operations. The large female population base serve as the untapped market potential along with the expansion growth opportunities in the future.
“India Cervical Cancer Screening Market Outlook 2022” research report discusses all aspects related to the cervical cancer screening market in India. Report gives comprehensive insight on the current accessible cervical screening approaches available in India. The various market dynamics discussed in the report offers unexplored opportunity for all stakeholders involved in the industry to expand their operations in Indian cervical screening market.
Cervical cancer is an important area of action for any cancer control programme because of the burden of disease, and the potential for effective prevention through screening. Cervical cancer hardly presents any symptoms in its early stages and it highlights the importance of regular screening for the disease. Screening is looking for cancer before a person has any symptoms. This can help to find the cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat.
Screening programs involve the testing of asymptomatic individuals with a precise screening test to identify those who likely to have the disease of interest and for the further investigation to confirm or exclude the disease. The aim of cancer screening is to prevent the cancer deaths and to improve the quality of life by finding cancers in early stage and by effectively treating them.
A choice to familiarize a screening program in public health services depends on the evidence that the benefits overshadow the harms of screening, disease burden, availability of suitable screening test, effective treatment, adequate resources, and efficient health services. Screening programs should achieve high participation for testing, diagnosis, and treatment. The population based cervical cancer screening programs have not yet been executed in many of the developing countries, despite the fact that cervical cancer has the greatest burden in developing countries, which is largely related to poverty, lack of resources and infrastructure and disqualification of women.
India accounts for 25% of global cervical incidences and death in annually in India. At present Women population accounts for approximately 49% of total Indian population. Among the total female population base, urban woman appears to be much aware of cervical screening test as compared to rural counterparts. Currently, there are VIA and Pap Smear test most common for cervical screening, but have their own disadvantages like inconvenience and less predictive and more confirmatory and surgical in nature.
Cervical cancer screening market in India is in still infancy stage. Currently the market is highly unorganized in the nature as most of the screening tests are performed in hospitals or under public programmes. The demand for cervical cancer screening is expected to rise with increasing awareness and growing concerns regarding second most common type of cancer causing large number of deaths among women in the country. The current degree of competition in terms of cervical screening in Indian is minimal with the availability of 2-3 players in the market.
There exist ample unexplored opportunity for various stake holders of the cervical screening market in India. Currently there is no big player in the market having national or regional level reach in Indian market. The entry restraints are minimal except the initial level of investment required to setup the operations. The large female population base serve as the untapped market potential along with the expansion growth opportunities in the future.
“India Cervical Cancer Screening Market Outlook 2022” research report discusses all aspects related to the cervical cancer screening market in India. Report gives comprehensive insight on the current accessible cervical screening approaches available in India. The various market dynamics discussed in the report offers unexplored opportunity for all stakeholders involved in the industry to expand their operations in Indian cervical screening market.
1. OVERVIEW OF THE CERVICAL CANCER
1.1 Introduction
1.2 Stages of the Cervical Cancer
1.2.1 Stage
1.2.2 Stage
1.2.3 Stage
1.2.4 Stage
1.2.5 Stage
2. OCCURRENCE RATE OF THE CERVICAL CANCER
2.1 Incidence of the Cervical Cancer in Indian States
2.2 Prevalence of Cervical Cancer in India
2.3 Existence of the Cervical Cancer around the World
3. RISK FACTORS FOR CERVICAL CANCER
3.1 Reasons for High Cervical Cancer Frequencies
3.2 Rural v/s Urban Cervical Cancer Risk Trends
4. CERVICAL CANCER SCREENING IN INDIA
4.1 Accessible Screening Approaches in India
4.1.1 Pap smear Method
4.1.2 Liquid Based Cytology Method
4.1.3 Visual Inspection with the Acetic Acid (VIA)
4.1.4 HPV DNA Test
4.2 Screening for Cervical Cancer in Developing Countries
4.3 Cervical Cancer Screening Kits
4.3.1 VIRO-Safe Screening Kit
4.3.2 The Digene Hc2 High Risk HPV DNA Test Kit
4.3.3 Magnivisualizer Detecting Device
5. THERAPEUTICS STRATEGIES FOR THE TREATMENT OF CERVICAL CANCER
5.1 Surgery
5.1.1 Hysterectomy
5.1.2 Pelvic Exenteration
5.1.3 Radical hysterectomy
5.1.4 Conization
5.1.5 Trachelectomy
5.2 Radiotherapy
5.2.1 External Beam Radiation Therapy (EBRT)
5.2.2 Branchytherapy
5.3 Chemotherapy
6. HPV VACCINATION IN INDIA
6.1 Introduction
6.2 Efficacy of the HPV Vaccine
6.3 Cost of HPV Vaccine for Developed & Developing Countries
7. VACCINATION PROGRAMS BY THE INDIAN GOVERNMENT
8. AVAILABLE HPV VACCINES IN INDIA
8.1 Quadrivalent Vaccine: - Gardasil
8.2 Bivalent Vaccine: - Cervarix
9. INDIA CERVICAL CANCER VACCINES MARKET ANALYSIS
9.1 India v/s Other Markets of Cervical Cancer Vaccine
9.2 Cervical Cancer Vaccine Market in India
10. HPV VACCINES MARKET DYNAMICS
10.1 Favorable Market Parameters
10.2 Challenges to the Development & Commercialization of HPV Vaccine
11. INDIA CERVICAL CANCER SCREENING MARKET FUTURE PROSPECTS
1.1 Introduction
1.2 Stages of the Cervical Cancer
1.2.1 Stage
1.2.2 Stage
1.2.3 Stage
1.2.4 Stage
1.2.5 Stage
2. OCCURRENCE RATE OF THE CERVICAL CANCER
2.1 Incidence of the Cervical Cancer in Indian States
2.2 Prevalence of Cervical Cancer in India
2.3 Existence of the Cervical Cancer around the World
3. RISK FACTORS FOR CERVICAL CANCER
3.1 Reasons for High Cervical Cancer Frequencies
3.2 Rural v/s Urban Cervical Cancer Risk Trends
4. CERVICAL CANCER SCREENING IN INDIA
4.1 Accessible Screening Approaches in India
4.1.1 Pap smear Method
4.1.2 Liquid Based Cytology Method
4.1.3 Visual Inspection with the Acetic Acid (VIA)
4.1.4 HPV DNA Test
4.2 Screening for Cervical Cancer in Developing Countries
4.3 Cervical Cancer Screening Kits
4.3.1 VIRO-Safe Screening Kit
4.3.2 The Digene Hc2 High Risk HPV DNA Test Kit
4.3.3 Magnivisualizer Detecting Device
5. THERAPEUTICS STRATEGIES FOR THE TREATMENT OF CERVICAL CANCER
5.1 Surgery
5.1.1 Hysterectomy
5.1.2 Pelvic Exenteration
5.1.3 Radical hysterectomy
5.1.4 Conization
5.1.5 Trachelectomy
5.2 Radiotherapy
5.2.1 External Beam Radiation Therapy (EBRT)
5.2.2 Branchytherapy
5.3 Chemotherapy
6. HPV VACCINATION IN INDIA
6.1 Introduction
6.2 Efficacy of the HPV Vaccine
6.3 Cost of HPV Vaccine for Developed & Developing Countries
7. VACCINATION PROGRAMS BY THE INDIAN GOVERNMENT
8. AVAILABLE HPV VACCINES IN INDIA
8.1 Quadrivalent Vaccine: - Gardasil
8.2 Bivalent Vaccine: - Cervarix
9. INDIA CERVICAL CANCER VACCINES MARKET ANALYSIS
9.1 India v/s Other Markets of Cervical Cancer Vaccine
9.2 Cervical Cancer Vaccine Market in India
10. HPV VACCINES MARKET DYNAMICS
10.1 Favorable Market Parameters
10.2 Challenges to the Development & Commercialization of HPV Vaccine
11. INDIA CERVICAL CANCER SCREENING MARKET FUTURE PROSPECTS
LIST OF FIGURES
Figure 1-1: Demonstration of Tumor Formation in Cervix
Figure 1-2: Cervical Cancer Stages
Figure 3-1: Factors for the Occurrence of Cervical Cancer
Figure 3-2: Burden of Cervical Cancer in India
Figure 4-1: Cervical Cancer Screening Approaches
Figure 4-2: India - Market Opportunity for Pap Smear Test (US$ Billion), 2017 till 2022
Figure 4-3: India - Market Opportunity for Pap Smear Test (INR Crore), 2017 till 2022
Figure 4-4: Visual Inspection with Acetic Acid Test Performance
Figure 4-5: Cervical Cancer Screening Programme Barriers
Figure 5-1: Treatment Approaches for Cervical Cancer
Figure 6-1: Market Price of HPV Vaccine in US & India (US$)
Figure 9-1: Segmentation of the Global Cervical Cancer Vaccine Market (%)
Figure 9-2: Three Regional Markets with the Growth Potential in World
Figure 9-3: India – Market Opportunity for Cervarix & Gardasil Vaccine at Annual Dosage Rate (US$ Billion), 2017 till 2022
Figure 9-4: India – Market Opportunity for Cervarix & Gardasil Vaccine at Annual Dosage Rate (INR Crore), 2017 till 2022
Figure 10-1: Favorable Market Drivers for the HPV Vaccine Market
Figure 10-2: Limiting Factors for the Cervical Cancer Market Growth
Figure 1-1: Demonstration of Tumor Formation in Cervix
Figure 1-2: Cervical Cancer Stages
Figure 3-1: Factors for the Occurrence of Cervical Cancer
Figure 3-2: Burden of Cervical Cancer in India
Figure 4-1: Cervical Cancer Screening Approaches
Figure 4-2: India - Market Opportunity for Pap Smear Test (US$ Billion), 2017 till 2022
Figure 4-3: India - Market Opportunity for Pap Smear Test (INR Crore), 2017 till 2022
Figure 4-4: Visual Inspection with Acetic Acid Test Performance
Figure 4-5: Cervical Cancer Screening Programme Barriers
Figure 5-1: Treatment Approaches for Cervical Cancer
Figure 6-1: Market Price of HPV Vaccine in US & India (US$)
Figure 9-1: Segmentation of the Global Cervical Cancer Vaccine Market (%)
Figure 9-2: Three Regional Markets with the Growth Potential in World
Figure 9-3: India – Market Opportunity for Cervarix & Gardasil Vaccine at Annual Dosage Rate (US$ Billion), 2017 till 2022
Figure 9-4: India – Market Opportunity for Cervarix & Gardasil Vaccine at Annual Dosage Rate (INR Crore), 2017 till 2022
Figure 10-1: Favorable Market Drivers for the HPV Vaccine Market
Figure 10-2: Limiting Factors for the Cervical Cancer Market Growth
LIST OF TABLES
Table 2-1: Prevalence of Cervical Cancer in India
Table 4-1: Available Screening kits with the Market Price
Table 7-1: Challenges and the Solutions to the Project Implementation
Table 8-1: Bivalent and Quadrivalent HPV Vaccine
Table 2-1: Prevalence of Cervical Cancer in India
Table 4-1: Available Screening kits with the Market Price
Table 7-1: Challenges and the Solutions to the Project Implementation
Table 8-1: Bivalent and Quadrivalent HPV Vaccine
